Signaturefd LLC Boosts Stock Position in Mesoblast Limited (NASDAQ:MESO)

Signaturefd LLC raised its position in shares of Mesoblast Limited (NASDAQ:MESO) by 64.7% during the 4th quarter, Holdings Channel reports. The firm owned 9,067 shares of the company’s stock after buying an additional 3,561 shares during the quarter. Signaturefd LLC’s holdings in Mesoblast were worth $180,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the company. Strategic Financial Concepts LLC acquired a new position in shares of Mesoblast in the 4th quarter valued at about $2,744,000. Jane Street Group LLC lifted its holdings in shares of Mesoblast by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after buying an additional 26,959 shares during the period. Clayton Financial Group LLC acquired a new position in shares of Mesoblast in the 4th quarter valued at about $275,000. Ballentine Partners LLC acquired a new position in shares of Mesoblast in the 4th quarter valued at about $222,000. Finally, Lindbrook Capital LLC lifted its holdings in shares of Mesoblast by 70.9% in the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock valued at $43,000 after buying an additional 901 shares during the period. Hedge funds and other institutional investors own 1.43% of the company’s stock.

Mesoblast Stock Performance

NASDAQ MESO opened at $13.94 on Friday. Mesoblast Limited has a twelve month low of $2.08 and a twelve month high of $22.00. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. The stock has a 50-day moving average of $16.66 and a 200 day moving average of $12.90.

Analyst Upgrades and Downgrades

MESO has been the subject of several analyst reports. Piper Sandler reissued an “overweight” rating and issued a $24.00 price objective (up previously from $15.00) on shares of Mesoblast in a report on Friday, February 7th. Jefferies Financial Group cut Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. Finally, Cantor Fitzgerald raised Mesoblast to a “strong-buy” rating in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Mesoblast presently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.